SCHEMBL1552344

SCHEMBL1552344

O=c1c(-c2cccc(C(F)(F)F)c2Cl)nn(Cc2ccc(F)cc2F)c2cc(Cl)ccc12

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 6/20 0.47
NR1H3 Q13133 6/20 0.47
NR1I2 O75469 2/20 0.40
NR3C1 P04150 2/20 0.40
AR P10275 1/20 0.40
RXRA P19793 1/20 0.40
GUCY1A1 Q02108 4/20 0.40
GUCY1B1 Q02153 4/20 0.40
PDE5A O76074 1/20 0.40
RORC P51449 8/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1551471 0.93 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1551636 0.93 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1974882 0.91 NR1H2 (0.44) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1551071 0.89 PDE5A (0.42) NR1H2NR1H3GUCY1A1GUCY1B1PDE5A
SCHEMBL1551078 0.88 PDE5A (0.42) NR1H2NR1H3GUCY1A1GUCY1B1PDE5A
SCHEMBL1551027 0.85 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1976393 0.83 NR1H2 (0.46) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1551482 0.82 NR1H2 (0.44) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1551442 0.82 NR1H2 (0.42) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1552322 0.81 NR1H2 (0.53) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313376-B1 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-24 EP claimed
US-8410099-B2 Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof SANOFI (FR) 2013-04-02 US claimed
JP-2011527323-A 2011-10-27 JP claimed
US-20110144115-A1 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US claimed
EP-2313376-A2 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2011-04-27 EP claimed
WO-2010004215-A2 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-01-14 WO claimed
EP-2313376-B1 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-24 EP disclosed
US-8410099-B2 Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof SANOFI (FR) 2013-04-02 US disclosed
US-20110144115-A1 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144115-A1 SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CNR1, CNR2, GPR18 NR1H2 535/4885NR1H3 458/4885NR1I2 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.